ISSN: 0006-4971

Journal Home

Blood Q1 Unclaimed

Elsevier BV United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Acceptance of manuscripts is based on the originality and importance of the observations or investigations, the quality of the work and validity of the evidence, the clarity of presentation, and the relevance to our readership and field. All articles are expected to be concise, well organized and clearly written. It has an SJR impact factor of 4,927.

Blood focuses its scope in these topics and keywords: cell, cells, patients, leukemia, stem, chronic, t, blood, hematopoietic, risk, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Biochemistry (Q1) Cell Biology (Q1) Hematology (Q1) Immunology (Q1)

Price

3170 €

Inmediate OA

NPD

Embargoed OA

910 €

Non OA

Metrics

4,927

SJR Impact factor

506

H Index

900

Total Docs (Last Year)

2535

Total Docs (3 years)

30720

Total Refs

21405

Total Cites (3 years)

1757

Citable Docs (3 years)

8.23

Cites/Doc (2 years)

34.13

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Nature Cell Biology Q1
Molecular Cell Q1
Genome Biology Q1
Nature Microbiology Q1
Cell Stem Cell Q1

Compare this journals

Aims and Scope

Best articles by citations

HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy

Busulfan bioavailability

Epstein-Barr virus associated B-cell lymphoproliferation in an infant treated for acute lymphoblastic leukemia [letter]

JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma

Expression and function of the endothelial protein C receptor in human neutrophils

Evidence-based focused review of the role of radiation therapy in the treatment of early-stage Hodgkin lymphoma

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome

Eosinophils are a major intravascular location for tissue factor storage and exposure

Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma

Monoclonal T-cell expansions in asymptomatic individuals and in patients with large granular leukemia consist of cytotoxic effector T cells expressing the activating CD94:NKG2C/E and NKD2D killer cell receptors

IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis

SHOW MORE ARTICLES

Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes

Dermal and pulmonary inflammatory disease in E-selectin and P-selectin double-null mice is reduced in triple-selectin-null mice

Cell-surface trafficking and release of flt3 ligand from T lymphocytes is induced by common cytokine receptor gamma-chain signaling and inhibited by cyclosporin A

Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand

Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma

Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Clonotypic B cells in classic Hodgkin lymphoma

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event

Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma